• 1
    Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24: 6839.
  • 2
    Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50: 184450.
  • 3
    Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009; 104: 8617.
  • 4
    Sattar N, Scherbakova O, Ford I et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004; 53: 285560.
  • 5
    Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54: 31407.
  • 6
    Kim DJ, Noh JH, Cho NH et al. Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med. 2005; 22: 113440.
  • 7
    Doi Y, Kubo M, Yonemoto K et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: The Hisayama Study. Obes Res. 2007; 15: 184150.
  • 8
    Ford ES, Schulze MB, Bergmann MM et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008; 31: 113843.
  • 9
    Nannipieri M, Gonzales C, Baldi S et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005; 28: 175762.
  • 10
    André P, Balkau B, Vol S, Charles MA, Eschwège E; DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care. 2007; 30: 235561.
  • 11
    Lee DS, Evans JC, Robins SJ et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007; 27: 12733.
  • 12
    Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004; 27: 142732.
  • 13
    Xiang J, Li XY, Xu M et al. Zinc Transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Chinese. J Clin Endocrinol Metab. 2008; 93: 410712.
  • 14
    Xu M, Li XY, Wang JG et al. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. Diabetologia. 2009; 52: 15119.
  • 15
    Rosell M, De Faire U, Hellénius ML. Low prevalence of the metabolic syndrome in wine drinkers – is it the alcohol beverage or the lifestyle? Eur J Clin Nutr. 2003; 57: 22734.
  • 16
    Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ). Available at: Accessed May 1, 2010.
  • 17
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 248697.
  • 18
    Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005; 366: 105962.
  • 19
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 9607.
    Direct Link:
  • 20
    Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 138795.
  • 21
    Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43: 50814.
  • 22
    Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 86573.
  • 23
    Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002; 87: 30238.
  • 24
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 148795.
  • 25
    Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009; 32: 74150.
  • 26
    Paolicchi A, Emdin M, Ghliozeni E et al. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation. 2004; 109: 1440.